Payment overview · 2025
General Payments
$25,517.67
179 reported records · 32 companies
Healthcare provider profile · identity verified
Luisa Solis-Cohen, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LITTLETON, CO · NPI 1215299193
Verified facts
What the public records show
CMS Open Payments records show Luisa Solis-Cohen, M.D. received $25,517.67 in general payments during 2025 across 179 reported records.
Neurocrine BioSciences, Inc. accounted for 72.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gocovri, Ingrezza.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Rytary by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18,532.00 | 72.6% | 33 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $4,001.80 | 15.7% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $692.55 | 2.7% | 33 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $398.13 | 1.6% | 23 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $243.99 | 1.0% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$233.41 | 0.9% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $180.81 | 0.7% | 10 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.93 | 0.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.40 | 0.5% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $83.25 | 0.3% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$79.90 | 0.3% | 3 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $79.63 | 0.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $75.00 | 0.3% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $72.08 | 0.3% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $54.93 | 0.2% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $52.85 | 0.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $47.00 | 0.2% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $42.42 | 0.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.08 | 0.2% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$33.07 | 0.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $30.69 | 0.1% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $30.22 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.45 | 0.1% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $27.70 | 0.1% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $25.43 | 0.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.63 | 0.1% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $24.62 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.93 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.08 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.84 | 0.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.46 | 0.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.39 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,052.00 | 4 |
| Consulting Fee | $6,617.50 | 2 |
| Food and Beverage | $3,783.29 | 159 |
| Honoraria | $3,020.00 | 3 |
| Travel and Lodging | $1,044.88 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18,532.00 | 33 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $3,082.25 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $349.90 | 21 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $320.58 | 8 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $255.78 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $248.57 | 16 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $219.41 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $160.63 | 9 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $155.93 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.35 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $142.35 | 10 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $134.68 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $106.19 | 7 | 2025 |
Source payment records
|
|||||
| SENSIGHT Normalized: sensight |
Device | Medtronic, Inc. | $98.73 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $83.25 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $79.90 | 3 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $79.63 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $59.63 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $59.06 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $54.93 | 2 | 2025 |
Source payment records
|
|||||
| Vercise Normalized: vercise |
Device | Boston Scientific Corporation | $49.63 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.11 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $30.69 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $30.22 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $29.45 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| REYVOW Normalized: reyvow |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $6.63 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $6.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gocovri gocovri |
2025 | Gocovri | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
210 | 45 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 466 | 163 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 230 | 69 |
| Rytary | Carbidopa/Levodopa | 210 | 45 |
| Donepezil Hcl | Donepezil Hcl | 149 | 53 |
| Gabapentin | Gabapentin | 102 | 40 |
| Amantadine | Amantadine Hcl | 77 | 25 |
| Clonazepam | Clonazepam | 75 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 16 |
| Gocovri | Amantadine Hcl | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 14 |
| Sertraline Hcl | Sertraline Hcl | 39 | 15 |
| Primidone | Primidone | 33 | 12 |
| Buspirone Hcl | Buspirone Hcl | 31 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | 12 |
| Ingrezza | Valbenazine Tosylate | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Droxidopa | Droxidopa | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25,517.67 · 179 records | Neurocrine BioSciences, Inc. | AJOVY, AMPYRA, BOTOX, CREXONT, CUTAQUIG, DAYBUE, EMGALITY, FIRDAPSE, Gamunex-C, General - DBS, Gocovri, Hizentra, INBRIJA, INFINITY, INGREZZA, KISUNLA, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PERCEPT PC BRAINSENSE, QALSODY, QULIPTA, QUTENZA, REXULTI, REYVOW, Radicava, Rystiggo, SENSIGHT, SKYCLARYS, SPINRAZA, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, Vercise, WAINUA, WAKIX, Xeomin, ZAVZPRET, ZEPOSIA, ZTLido | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gocovri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amneal Pharmaceuticals LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error